SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001867096-23-000056
Filing Date
2023-04-26
Accepted
2023-04-26 16:14:52
Documents
5
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2023proxystatement.htm DEF 14A 489091
2 imagea.jpg GRAPHIC 17751
3 pauledicksignaturea.jpg GRAPHIC 37016
4 xerspcv4r1_pagex1a.jpg GRAPHIC 323472
5 xerspcv4r1_pagex2a.jpg GRAPHIC 153834
  Complete submission text file 0001867096-23-000056.txt   1217070
Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40880 | Film No.: 23849902
SIC: 2834 Pharmaceutical Preparations